Severe Hypoalbuminemia Increases the Risk of Thrombocytopenia in Critically Ill Adult Patients Receiving Teicoplanin

  • Md Jahidul Hasan Clinical Pharmacy Services, Department of Pharmacy, Square Hospitals Ltd., 18/F, Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath, Dhaka-1205, Bangladesh
  • Raihan Rabbani Internal Medicine and ICU, Square Hospitals Ltd., 18/F, Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath Dhaka-1205, Bangladesh
  • Sitesh C Bachar Department of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh
Keywords: Teicoplanin, thrombocytopenia, severe hypoalbuminemia, adverse drug reaction.

Abstract

Teicoplanin is a drug of choice for treating infections by gram positive microorganisms. Teicoplanininduced thrombocytopenia is an adverse drug reaction found in critically ill patients receiving teicoplanin. The aim of this observational study was to analyze the increased risk of occurring teicoplanin-induced thrombocytopenia in patients with severe hypoalbuminemia than the patients having normal blood-albumin level. A 5-month long study was conducted in an adult-ICU department on 42 critically ill adult patients. In this study, 17 (40.48%, n=42) patients developed teicoplanin-induced thrombocytopenia and among them, 14 patients (60.87%, n=23) were suffering from severe hypoalbuminemia during the initiation of teicoplanin therapy. All the events were normalized within 48 hours after discontinuing the teicoplanin. In this study, we found that teicoplanin-induced thrombocytopenia is one of the most common adverse drug reaction developed in critically ill adult patients and concurrent severe hypoalbuminemia may enormously increase the risk of this adverse drug reaction.

Dhaka Univ. J. Pharm. Sci. 18(2): 153-157, 2019 (December)

Downloads

Download data is not yet available.
Abstract
94
PDF
77
Published
2019-09-22
How to Cite
Hasan, M. J., Rabbani, R., & Bachar, S. (2019). Severe Hypoalbuminemia Increases the Risk of Thrombocytopenia in Critically Ill Adult Patients Receiving Teicoplanin. Dhaka University Journal of Pharmaceutical Sciences, 18(2), 153-157. https://doi.org/10.3329/dujps.v18i2.43257
Section
Articles